Innovating For Patients
Trevena is a biopharmaceutical company focused on developing and commercializing novel medicines for patients with central nervous system (CNS) disorders.
About Us
Targeted and Innovative CNS Therapies
Trevena’s novel pipeline includes five product candidates that are being developed for areas of critical need in CNS and other disorders. All of the company’s pipeline assets are new chemical entities with unique mechanisms of action that target well-known receptors.
| Program | Molecular Target | Therapeutic Target | Current Phase | PC | PH1 | PH2 | PH3 | NDA |
|---|---|---|---|---|---|---|---|---|
| Oliceridine | Mu receptor | Moderate-to-severe acute pain | NDA | PC complete | PH1 complete | PH2 complete | PH3 complete | NDA in progress |
| TRV250 | Delta receptor | Acute migraine | PH1 | PC complete | PH1 in progress | PH2 not started | PH3 not started | NDA not started |
| TRV734 | Mu receptor | Opioid use disorder | PH1 | PC complete | PH1 in progress | PH2 not started | PH3 not started | NDA not started |
| TRV045 | S1P receptor | CNS disorders | PC | PC in progress | PH1 not started | PH2 not started | PH3 not started | NDA not started |
| TRV027 | AT1 receptor | Acute lung injury / ARDS (COVID-19) | PH1 | PC complete | PH1 in progress | PH2 not started | PH3 not started | NDA not started |
All pipeline assets are Investigational Products not approved by FDA for sale or distribution in the US.
